Zurich Cantonal Bank
SPRY icon

Zurich Cantonal Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Zurich Cantonal Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,662
Closed -$136K – 3385
2025
Q4 		$136K Buy
+11,662
New +$113K ﹤0.01% 2338

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Zurich Cantonal Bank's SPRY Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 11,662 shares worth $93.6K. The stake represents ﹤0.01% of the portfolio and ranks #2387 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in SPRY as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in SPRY in Q1 2023 and has held it in 12 quarters since. The position peaked at $129K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Zurich Cantonal Bank held 11,662 shares of ARS Pharmaceuticals worth $93.6K as of Q1 2026.
  • ARS Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #2387 holding.
  • Zurich Cantonal Bank first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • Zurich Cantonal Bank's ARS Pharmaceuticals position peaked at $129K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.